CCS1477
CCS-1477 (CCS1477) is a potent, selective and orally bioavailable inhibitor of the Bromodomain of p300 and CBP, binding to the targets with high affinity (Kd = 1.3/1.7nM) and selectivity (Kd = 222nM; BRD4). E1A binding protein (p300) and CREB binding protein (CBP) are two closely related transcriptional activators of androgen receptor (AR) and its variant forms. CCS-1477 enhances degradation of numerous cellular proteins including the AR and AR variants in prostate cancer cells.
|
|
|
Cat. No.: EX-A3687 | Purity: >98% |
|  |
| Chemical structure of CCS1477 |
For research only, Do not use for Human!
Synonyms | Inobrodib |
---|
Synonyms 2 | CCS-1477 |
---|
CAS No. | 2222941-37-7 |
---|
Purity | >98% |
---|
Formula | C30H32F2N4O3 |
---|
Mol Weight | 534.5969 |
---|
Appearance | solid powder |
---|
Solubility | Soluble in DMSO |
---|
Shelf Life | >2 years if stored properly |
---|
Storage | Powder -20℃ 2 years; In solvent -20℃ 1 month; |
---|
Shipping | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
---|
|
---|
| |
---|
Reference: | [1]. Rasool RU, et al. Toppling the HAT to Treat Lethal Prostate Cancer. Cancer Discov. 2021;11(5):1011-1013.
[2]. N. Pegg, et al, Characterization of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer, Journal of Clinical Oncology 2017 35:15_suppl, 11590-11590
[3]. J. S. De Bono, et al, Journal of Clinical Oncology 2019 37:15_suppl, TPS5089-TPS5089
|
---|
CoA | CoA of CCS1477 |
---|
Smiles: | O=C1N(C2=CC=C(F)C(F)=C2)[C@H](C3=NC4=CC(C5=C(C)ON=C5C)=CC=C4N3[C@H]6CC[C@H](OC)CC6)CCC1 |
---|
KEYWORDS: buy CCS1477 | CCS1477 supplier | purchase | cost | manufacturer | order | distributor | buy 2222941-37-7 | 2222941-37-7 supplier